News

COYA 302 slows disease progression, lowers biomarkers: Trial

COYA 302, Coya Therapeutics’ experimental immune-modulating combination therapy, safely slows disease progression and reduces levels of disease biomarkers in people with amyotrophic lateral sclerosis (ALS). That’s according to the now-published results from a small proof-of-concept Phase 1 clinical trial (NCT06307301) that tested the therapy in four ALS…

ALS scholarship program to help students who have lost parents

The nonprofit organization ALS Northwest has partnered with the Oregon State Treasury to establish a college scholarship program through the state-administered Oregon College Savings Plan for students who have lost parents or guardians to amyotrophic lateral sclerosis (ALS). ALS Northwest will administer the Elinore Nudelman ALS College…

Eli Lilly to develop, market ALS therapy for UNC13A function

Eli Lilly has acquired the global exclusive rights to develop and market QRL-204, QurAlis’ investigational therapy for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) that’s designed to restore UNC13A function in nerve cells. UNC13A is an essential regulator of neurotransmitter release at synapses, a key process…

InnoVision to handle awareness campaigns for ALS Association

The ALS Association has selected InnoVision Marketing Group as its agency of record for creating media campaigns to raise awareness of amyotrophic lateral sclerosis (ALS) and the association’s mission of improving the lives of people with ALS. InnoVision, which has previously collaborated with the nonprofit on specific initiatives…